HCW Biologics Inc.
HCWB · XNASCIK 1828673fmd_1P8HBR74QKVC0ZAQGFSV4T94BDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 4 | 0 | 7 | 3 | 3 | 0 |
| Cost of revenue | – | 0 | 4 | 2 | 2 | 0 |
| Gross profit | – | 0 | 3 | 1 | 1 | 0 |
| Realized investment gains (losses) | – | – | 0 | 0 | 0 | (0) |
| Research and development | 7 | 8 | 9 | 8 | 6 | 5 |
| Total operating expenses | 10 | 13 | 18 | 26 | 30 | 13 |
| Operating income | (6) | (13) | (15) | (26) | (29) | (13) |
| Interest expense | – | 0 | 0 | 0 | 1 | 1 |
| Interest and investment income | 0 | 1 | – | – | – | – |
| Other non-operating income (expense) | – | – | – | – | (1) | 0 |
| Income before taxes | (6) | (13) | (15) | (25) | (30) | (8) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (6) | (13) | (15) | (25) | (30) | (8) |
| Net income | (6) | (13) | (15) | (25) | (30) | (8) |
| Net income to common shareholders | (7) | (13) | – | – | (30) | (22) |